GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (NAS:BGNE) » Definitions » Piotroski F-Score

BeiGene (BeiGene) Piotroski F-Score : 3 (As of May. 06, 2024)


View and export this data going back to 2016. Start your Free Trial

What is BeiGene Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

BeiGene has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for BeiGene's Piotroski F-Score or its related term are showing as below:

BGNE' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 3   Max: 6
Current: 3

During the past 11 years, the highest Piotroski F-Score of BeiGene was 6. The lowest was 3. And the median was 3.


BeiGene Piotroski F-Score Historical Data

The historical data trend for BeiGene's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Piotroski F-Score Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 4.00 6.00 3.00 3.00

BeiGene Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 5.00 3.00 3.00 3.00

Competitive Comparison of BeiGene's Piotroski F-Score

For the Biotechnology subindustry, BeiGene's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeiGene's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeiGene's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where BeiGene's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -348.431 + -381.137 + 215.413 + -367.553 = $-882 Mil.
Cash Flow from Operations was -563.777 + -293.888 + -78.15 + -221.638 = $-1,157 Mil.
Revenue was 447.801 + 595.261 + 781.308 + 634.409 = $2,459 Mil.
Gross Profit was 366.012 + 499.271 + 684.999 + 528.577 = $2,079 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(6379.29 + 5956.775 + 5728.736 + 5524.879 + 5805.275) / 5 = $5878.991 Mil.
Total Assets at the begining of this year (Dec22) was $6,379 Mil.
Long-Term Debt & Capital Lease Obligation was $220 Mil.
Total Current Assets was $4,203 Mil.
Total Current Liabilities was $1,810 Mil.
Net Income was -435.198 + -565.726 + -557.556 + -445.335 = $-2,004 Mil.

Revenue was 306.626 + 341.572 + 387.628 + 380.095 = $1,416 Mil.
Gross Profit was 241.389 + 270.399 + 311.085 + 306.573 = $1,129 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(8535.525 + 8021.388 + 7378.207 + 6726.013 + 6379.29) / 5 = $7408.0846 Mil.
Total Assets at the begining of last year (Dec21) was $8,536 Mil.
Long-Term Debt & Capital Lease Obligation was $244 Mil.
Total Current Assets was $5,207 Mil.
Total Current Liabilities was $1,469 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

BeiGene's current Net Income (TTM) was -882. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

BeiGene's current Cash Flow from Operations (TTM) was -1,157. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-881.708/6379.29
=-0.13821413

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-2003.815/8535.525
=-0.23476178

BeiGene's return on assets of this year was -0.13821413. BeiGene's return on assets of last year was -0.23476178. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

BeiGene's current Net Income (TTM) was -882. BeiGene's current Cash Flow from Operations (TTM) was -1,157. ==> -1,157 <= -882 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=219.869/5878.991
=0.0373991

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=243.665/7408.0846
=0.03289177

BeiGene's gearing of this year was 0.0373991. BeiGene's gearing of last year was 0.03289177. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=4203.414/1810.113
=2.3221832

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=5207.078/1468.528
=3.54578054

BeiGene's current ratio of this year was 2.3221832. BeiGene's current ratio of last year was 3.54578054. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

BeiGene's number of shares in issue this year was 104.074. BeiGene's number of shares in issue last year was 103.768. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2078.859/2458.779
=0.84548428

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1129.446/1415.921
=0.79767586

BeiGene's gross margin of this year was 0.84548428. BeiGene's gross margin of last year was 0.79767586. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=2458.779/6379.29
=0.38543145

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=1415.921/8535.525
=0.16588564

BeiGene's asset turnover of this year was 0.38543145. BeiGene's asset turnover of last year was 0.16588564. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

BeiGene has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

BeiGene  (NAS:BGNE) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


BeiGene Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of BeiGene's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene (BeiGene) Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Executives
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Chan Henry Lee officer: SVP, General Counsel 55 CAMBRIDGE PARKWAY, SUITE 700W, CAMBRIDGE MA 02142
Julia Aijun Wang officer: Chief Financial Officer C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Lai Wang officer: Global Head of R&D C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Xiaobin Wu officer: President and GM China C/O MOURANT OZANNES CRP SVCS CAYMAN LTD, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Sanders Corazon (corsee) D. director C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
Hillhouse Capital Advisors, Ltd. 10 percent owner OFFICE #122, WINDWARD 3 BUILDING, REGATTA OFFICE PARK, WEST BAY ROAD, GRAND CAYMAN E9 KY1-9006
Xiaodong Wang director C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
John Oyler director, 10 percent owner, officer: Chief Executive Office C/O GENTA INC, 3550 GENERAL ATOMICS CT BLDG 9, SAN DIEGO CA 92121
Alessandro Riva director C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Margaret Dugan director C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Jane Huang officer: CMO, Hematology C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Amgen Inc 10 percent owner ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Howard Liang officer: CFO & CSO C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Timothy Yung-cheng Chen director LSI LOGIC CORP, 1621 BARBER LANE, MILPITAS CA 95035

BeiGene (BeiGene) Headlines

From GuruFocus

BAKER BROS. ADVISORS LP Bolsters Position in BeiGene Ltd

By GuruFocus Research 11-15-2023